ISRAEL'S PTSD CRISIS

The October 7 attacks triggered a severe mental health crisis in Israel, with PTSD and related conditions rising far beyond previous levels. Before October 7, in one district, the Israeli Ministry of Health was treating roughly 162 PTSD patients per year; today, they are facing a backlog of about 5,000 new PTSD patients every month seeking help. This represents an enormous, system‑straining increase in need, far more than a simple “doubling” of cases.

In an effort to respond, the Ministry conducted a broad review of available PTSD treatments and selected a protocol they believed could be scaled to meet this demand. After implementation, however, they found that this protocol was not delivering the level of symptom reduction and functional improvement they needed, leaving many patients still significantly impaired despite receiving care. Recognizing that their current solution was not working, they began looking for next‑generation approaches that targeted the underlying brain dysfunction in PTSD more directly.

As part of that search, they invited our team at the Neural Science Institute to present Neural Pathway Therapy and to share our outcomes in PTSD and related conditions. On January 15th, we met with senior Ministry leaders to compare their current PTSD protocol side‑by‑side with our neuromodulation‑based approach. After reviewing our protocol, clinical logic, and outcome data, they acknowledged that Neural Pathway Therapy represents a next‑generation strategy and appears to offer a more comprehensive neuromodulation approach, particularly in its ability to regulate disrupted brain activity and support lasting symptom relief

Based on that evaluation, the Ministry asked us to run an initial pilot with 50 PTSD patients treated using Neural Pathway Therapy, so they can formally assess outcomes within their own system. The shared understanding is that, if the results from these 50 patients align with our prior experience, they intend to move forward with having us help address their backlog of  5,000 PTSD patients per month. This would allow them to scale a more effective, neuroscience‑driven intervention to thousands of people who urgently need relief.

To make Phase One possible, we are raising $200,000 specifically to fund treatment for these first 50 patients. One hundred percent of the funds go directly to patient care: at $4,000 per patient, the full $200,000 (50 patients × $4,000) is used so that each member of this initial cohort can receive Neural Pathway Therapy at no cost to them. We have already started this work and have just finished treating our first patient in the program; the video above shares their story and illustrates the kind of change this approach can bring to someone living with severe PTSD.